Taro Pharmaceutical Industries Ltd (TARO)

NYSE

Currency in USD

42.97

0.00(0.00%)

Closed21/06

Fair Value

Day's Range

42.94

42.98

52 wk Range

32.87

45.76

TARO Income Statement

Featured here, the Income Statement (earnings report) for Taro Pharmaceutical Industries Ltd, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2015

31/03

2016

31/03

2017

31/03

2018

31/03

2019

31/03

2020

31/03

2021

31/03

2022

31/03

2023

31/03

2024

31/03

Total Revenues

644.77

548.97

561.35

572.95

629.18

Total Revenues Growth

-3.75%

-14.86%

+2.25%

+2.07%

+9.81%

Cost Of Revenues

245.04

252.31

268.21

304.63

324.2

Gross Profit

399.73

296.66

293.14

268.32

304.98

Gross Profit Growth

-10.32%

-25.78%

-1.19%

-8.46%

+13.66%

Gross Profit Margin %

62%

54.04%

52.22%

46.83%

48.47%

Other Operating Expenses, Total

153.19

151.51

168.22

250.61

297.67

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-0.01%	-1.1%	+11.03%	+48.98%	+18.78%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	59.78	60.15	54.54	52.24	64.54
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	93.41	91.36	113.68	198.37	233.14
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

246.54

145.15

124.92

17.71

7.31

Operating Income Growth

-15.72%

-41.12%

-13.94%

-85.82%

-58.74%

EBIT Margin %

38.24%

26.44%

22.25%

3.09%

1.16%

Net Interest Expenses

33.64

20.17

8.19

20.85

56.19

Net Interest Expenses Growth

+0.3%

-40.04%

-59.42%

+154.67%

+169.51%

Interest Expense, Total

-0.73

-1.36

-1.65

-1.25

-

Interest And Investment Income

34.37

21.54

9.84

22.1

56.19

Other Non Operating Expenses, Total

17.86

2.53

6.21

-0.35

4.99

EBT, Excl. Unusual Items

298.04

167.85

139.32

38.21

68.49

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-

-558.92

-61.46

-

14.18

EBT, Incl. Unusual Items

298.04

-391.07

77.86

38.21

82.67

EBT, Incl. Unusual Items Growth

-16.48%

-231.22%

+119.91%

-50.92%

+116.33%

EBT, Incl. Unusual Items Margin

46.22%

-71.24%

13.87%

6.67%

13.14%

Income Tax Expense

53.49

9.67

19.59

12.77

28.8

Net Income to Company

244.55

-400.74

58.27

25.45

53.87

Minority Interest

-0.31

14.09

-

-

-

Net Income

244.24

-386.65

58.27

25.45

53.87

Net Income Growth

-13.32%

-258.31%

+115.07%

-56.33%

+111.7%

Net Income Margin %

37.88%

-70.43%

10.38%

4.44%

8.56%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

244.24

-386.65

58.27

25.45

53.87

Basic EPS - Continuing Operations

6.35

-10.12

1.55

0.68

1.43

Basic EPS - Continuing Operations Growth

-12.13%

-259.35%

+115.3%

-56.26%

+111.7%

Diluted EPS - Continuing Operations

6.35

-10.12

1.55

0.68

1.43

Diluted EPS - Continuing Operations Growth

-12.13%

-259.35%

+115.3%

-56.26%

+111.7%

Basic Weighted Average Shares Outstanding

38.46

38.21

37.64

37.58

37.58

Diluted Weighted Average Shares Outstanding

38.46

38.21

37.64

37.58

37.58

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

267.92

168.83

150.83

49.84

38.4

EBITDA Growth

-13.88%

-36.98%

-10.66%

-66.96%

-22.95%

EBITDA Margin %

41.55%

30.75%

26.87%

8.7%

6.1%

EBIT